These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 23802529)

  • 1. Omalizumab for chronic urticaria.
    Maurer M; Rosén K; Hsieh HJ
    N Engl J Med; 2013 Jun; 368(26):2530. PubMed ID: 23802529
    [No Abstract]   [Full Text] [Related]  

  • 2. Omalizumab for chronic urticaria.
    Altman MC; Naimi DR
    N Engl J Med; 2013 Jun; 368(26):2528-30. PubMed ID: 23802532
    [No Abstract]   [Full Text] [Related]  

  • 3. Omalizumab for chronic urticaria.
    Benelli E; Ventura A
    N Engl J Med; 2013 Jun; 368(26):2528. PubMed ID: 23802531
    [No Abstract]   [Full Text] [Related]  

  • 4. Omalizumab for chronic urticaria.
    Wu K; Long H
    N Engl J Med; 2013 Jun; 368(26):2527-8. PubMed ID: 23802530
    [No Abstract]   [Full Text] [Related]  

  • 5. Commentary: Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.
    Sabroe RA
    Br J Dermatol; 2014 Jul; 171(1):13-5. PubMed ID: 25066289
    [No Abstract]   [Full Text] [Related]  

  • 6. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria: a critical appraisal.
    Durack A; Matin RN
    Br J Dermatol; 2014 Jul; 171(1):10-3. PubMed ID: 25066288
    [No Abstract]   [Full Text] [Related]  

  • 7. Response to: 'Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria: a critical appraisal'.
    Rosén K; Maurer M; Hsieh H; Saini S; Grattan C; Gimenéz-Arnau A; Agarwal S; Doyle R; Canvin J; Kaplan A; Casale T
    Br J Dermatol; 2014 Jul; 171(1):15-6. PubMed ID: 25066290
    [No Abstract]   [Full Text] [Related]  

  • 8. Extraordinary response to omalizumab in a child with severe chronic urticaria.
    Asero R; Casalone R; Iemoli E
    Eur Ann Allergy Clin Immunol; 2014 Jan; 46(1):41-2. PubMed ID: 24702874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omalizumab for chronic urticaria.
    Casale TB
    J Allergy Clin Immunol Pract; 2014; 2(1):118-9. PubMed ID: 24565785
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of omalizumab in a patient with three types of chronic urticaria.
    Vieira Dos Santos R; Locks Bidese B; Rabello de Souza J; Maurer M
    Br J Dermatol; 2014 Feb; 170(2):469-71. PubMed ID: 24102388
    [No Abstract]   [Full Text] [Related]  

  • 11. Omalizumab (Xolair) for the treatment of chronic idiopathic urticarial.
    Scheinfeld N
    Skinmed; 2014; 12(5):294-7. PubMed ID: 25632648
    [No Abstract]   [Full Text] [Related]  

  • 12. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.
    Maurer M; Rosén K; Hsieh HJ; Saini S; Grattan C; Gimenéz-Arnau A; Agarwal S; Doyle R; Canvin J; Kaplan A; Casale T
    N Engl J Med; 2013 Mar; 368(10):924-35. PubMed ID: 23432142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JID VisualDx Quiz: January 2015.
    Shabbir A; Kirsner RS
    J Invest Dermatol; 2015 Jan; 135(1):1-2. PubMed ID: 25501381
    [No Abstract]   [Full Text] [Related]  

  • 14. Chronic urticaria: omalizumab and review of therapeutic options.
    Bergstrom KG
    J Drugs Dermatol; 2013 Jun; 12(6):715-6. PubMed ID: 23839196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omalizumab in chronic urticaria.
    Metz M; Maurer M
    Curr Opin Allergy Clin Immunol; 2012 Aug; 12(4):406-11. PubMed ID: 22766620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement in quality of life impairment followed by relapse with 6-monthly periodic administration of omalizumab for severe treatment-refractory chronic urticaria and urticarial vasculitis.
    Kai AC; Flohr C; Grattan CE
    Clin Exp Dermatol; 2014 Jul; 39(5):651-2. PubMed ID: 24758481
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria.
    Mathias SD; Crosby RD; Zazzali JL; Maurer M; Saini SS
    Ann Allergy Asthma Immunol; 2012 Jan; 108(1):20-24. PubMed ID: 22192960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omalizumab in chronic spontaneous urticaria: patient-tailored tapering or planned discontinuation?
    Tontini C; Marinangeli L; Cognigni M; Bilò MB; Antonicelli L
    Ann Allergy Asthma Immunol; 2015 Aug; 115(2):147-8. PubMed ID: 26048249
    [No Abstract]   [Full Text] [Related]  

  • 19. A critical appraisal of omalizumab as a therapeutic option for chronic refractory urticaria/angioedema.
    Lang DM
    Ann Allergy Asthma Immunol; 2014 Apr; 112(4):276-9. PubMed ID: 24589165
    [No Abstract]   [Full Text] [Related]  

  • 20. Omalizumab in chronic urticaria: a retrospective series of 15 cases.
    Armengot-Carbo M; Velasco-Pastor M; Rodrigo-Nicolas B; Pont-Sanjuan V; Quecedo-Estebanez E; Gimeno-Carpio E
    Dermatol Ther; 2013; 26(3):257-9. PubMed ID: 23742285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.